RDP-58 (SangStat Medical)

Holtmann, M.M.

Idrugs the Investigational Drugs Journal 6(12): 1188-1194

2003


ISSN/ISBN: 1369-7056
PMID: 14666431
Document Number: 557549
RDP-58, a decapeptide with inhibitory effects on tumor necrosis factor synthesis, is under development by SangStat Medical Corp for the potential treatment of Crohn's disease and ulcerative colitis; phase II trials for both these indications commenced in October 2001. SangStat also initiated a phase I trial in chemotherapy-induced diarrhea in the first quarter of 2003 and anticipates initiating phase I trials in the gastrointestinal complications of HIV by the end of 2003.

Document emailed within 1 workday
Secure & encrypted payments